Wells Messersmith, MDEnriched profile
Professor of Medicine-Medical Oncology; Division Head, Division of Medical Oncology; Associate Director for Translational/Clinical Research, University of Colorado Cancer Center; Chief Medical Officer of Oncology Services, UCHealth · University of Colorado Cancer Center
Overview
Updated 14 Jul 2026
Wells Messersmith, MD, is Professor of Medicine-Medical Oncology at University of Colorado Cancer Center / University of Colorado School of Medicine (Anschutz Medical Campus). The public record shows 784 publications with 23,739 citations (h-index 70), centered on Colorectal Cancer, Pancreatic Cancer. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 2 companies, 4 NIH-funded awards (2007–2014).
- Most recent indexed publication: 2025 · Cancer research communications
- Top research focus: Colorectal Cancer
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Public positionssourced statements on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →criteriuminc.com ↗
- Member
NCI/CTEP Investigational Drug Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 1/PHASE2RecruitingNCT07147231 - A Study of NX-1607 in Adults With Advanced Malignancies
Sponsor: Nurix Therapeutics, Inc.
InvestigatorPhase 1RecruitingNCT05107674 - Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors
Sponsor: University of Colorado, Denver
InvestigatorPhase 3CompletedNCT03781154
Industry payments
Updated 14 Jul 2026
2 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20248 payments
- Amgen Inc.Program year20234 payments
- Amgen Inc.Program year20224 payments
NIH funding
Updated 14 Jul 2026
4 NIH research awards on record, funded 2007–2014 per NIH RePORTER. The latest:
- The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Johns Hopkins University
FY2026$1,854,447UM1CA186691 - The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Johns Hopkins University
FY2025$1,817,609UM1CA186691 - The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Johns Hopkins University
FY2024$1,727,315UM1CA186691
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
University of Colorado Cancer Center, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO 80045
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Editorial & leadership rolesjournal and society appointments
- Division Head
Division of Medical Oncology, University of Colorado School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.cuanschutz.edu ↗
- Associate Director for Translational/Clinical Research
University of Colorado Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Secondary affiliationsappointments beyond the home institution
- Director
Academic GI Cancer Consortium (AGICC), a Criterium-operated multi-institutional oncology CRO consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →criteriuminc.com ↗
Media & interviewspress, podcasts and appearances
- PharmaVoice/Criterium One-on-One video interview
discussing AGICC and GI cancer drug development
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →9news.com ↗
- Recurring video contributor/author on OncLive discussing colorectal cancer treatment
HER2-targeted therapy, and biomarkers
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- ResearchGate
researchgate.net/scientific-contributions/Wells-A-Messersmith-39387735
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Other
society.asco.org/people/wells-a-messersmith-md-facp
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →society.asco.org ↗ - X / Twitter
x.com/SunnieSKim/status/1883280314598035857
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
Universitair Ziekenhuis Leuven
- 1,845
- publications
- 177
- h-index
- 14
- trials
Josep Tabernero, MD, PhD
Vall d'Hebron Institut de Recerca
- 2,704
- publications
- 148
- h-index
- 19
- trials
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Charles Fuchs, MD, MPH
Yale Cancer Center
- 1,721
- publications
- 172
- h-index
- 7
- trials